Changes in metabolic parameters in psoriatic patients treated with secukinumab.
Hsuan Ning WangYu Huei HuangPublished in: Therapeutic advances in chronic disease (2020)
Our results suggest that obesity and hypertriglyceridemia still existed in patients despite the improved disease activity after secukinumab treatment. Higher baseline hs-CRP level and PASI-90 non-response were predictors for elevated triglyceride levels after treatment. Therefore, patient education, regular screening of the lipid profile, and weight control are recommended during the treatment of secukinumab.
Keyphrases
- ankylosing spondylitis
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- weight loss
- rheumatoid arthritis patients
- healthcare
- type diabetes
- metabolic syndrome
- ejection fraction
- newly diagnosed
- body mass index
- juvenile idiopathic arthritis
- peritoneal dialysis
- patient reported outcomes
- quality improvement
- replacement therapy
- skeletal muscle